Free Fall Alarms Offered as Part of Package
The Posey Company is offering its customers an “Economic Stimulus Package”: With a commitment of two sensor pads per month, per alarm for 2 years, customers will receive their choice of a free patient fall alarm, either the Posey Sitter Select or the Posey Keep-Safe Deluxe.
© Posey Company
Posey Fall Alarms help reduce the likelihood of patient falls and subsequent injuries by notifying caregivers of patient movement. The alarms provide the earliest possible warning that a patient is attempting to exit his or her bed, chair, or toilet and is at immediate risk of falling.
For more information on the Posey Economic Stimulus Package, contact 1-800-44-POSEY or http://www.posey.com.
Source.Posey Company. (2009, July 22). Posey Company launches new economic stimulus package [press release]. Arcadia, CA: Author.
Hyperglycemia Linked to Antipsychotic Use
Noting that an increasing number of older adults are being prescribed antipsychotic drugs for dementia, researchers of a study published in Archives of Internal Medicine have found that older patients with diabetes who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia, especially soon after beginning treatment.
The study involved 13,817 individuals age 66 and older (mean age = 78) with diabetes who began treatment with antipsychotic medications between April 1, 2002, and March 31, 2006. Each patient who was hospitalized for hyperglycemia during the observation period—through March 31, 2007, an average of 2 years of follow up—was considered a case and was matched with up to 10 control patients who were the same age and gender but were not hospitalized over the same time period. The researchers then compared the likelihood of hyperglycemia among those who were currently taking antipsychotic medications to those who had discontinued antipsychotic medications for more than 180 days.
Of the total sample, 1,515 (11%) were hospitalized for hyperglycemia. Those who were currently taking antipsychotic drugs had a higher risk of hospitalization than those who had stopped the medications more than 180 days ago. The risk was highest among those who were just starting antipsychotic drug treatment.
Source.“Antipsychotic Drugs Associated with High Blood Sugar in Older Adults with Diabetes.” (2009, July 23). Retrieved August 31, 2009, from http://www.newswise.com/articles/view/554593.
Product Enhancements Hope to Ease Catheter Use
Ethicon’s Biopatch® Protective Disk with CHG (chlorhexidine gluconate) will include new design elements and updated packaging to make it easier for nurses, surgeons, and other health care providers to apply the product correctly around catheters to reduce the risk of catheter-related bloodstream infections (CRBSIs).
Biopatch is placed directly on the skin at the point of catheter insertion and provides 7 days of continuous active antisepsis. In a clinical study published in the Journal of the American Medical Association, the use of Biopatch was associated with a 76% reduction in CRBSIs.
The enhanced design and packaging for Biopatch includes easy-to-follow instructions and clearly marked “up” arrows to signify correct application with respect to skin orientation of the product. In addition, Biopatch packaging now features color-coded elements designed to instantly identify the size and center-hole diameter of the product.
Source.“Ethicon Introduces New Product Enhancement and Packaging for BIOPATCH®To Improve Ease of Application for Patients with Catheters.” (2009, August 11). Retrieved September 2, 2009, from http://www.jnj.com/connect/news/all/20090811_110000.
New Anti-Arrhythmic Drug now Available
Approved by the U.S. Food and Drug Administration in July 2009, Multaq® (dronedarone) 400 mg tablets are now available in U.S. pharmacies. Multaq is an anti-arrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted.
In the landmark ATHENA trial, the efficacy and safety of Multaq was evaluated in patients with AF/AFL or a recent history of these conditions (71% of these patients had no heart failure, 29% had New York Heart Association class I–III stable heart failure). This trial showed that Multaq 400 mg twice daily, in addition to standard therapy, reduced the combined endpoint of cardiovascular hospitalization or death from any cause by 24% (p < 0.001) when compared with placebo, meeting the study’s primary endpoint.
Source.“Multaq®(Dronedarone) for Atrial Fibrillation or Atrial Flutter Now Available in the United States.” (2009, July 28). Retrieved September 2, 2009, from http://www.prnewswire.com/mnr/multaq/38911.
Effient Approved, Helps Reduce Artery Blockage
The U.S. Food and Drug Administration has approved Effient™ (prasugrel) tablets for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). Effient helps keep blood platelets from sticking together to form clots. Taking Effient with aspirin after PCI has been shown to reduce the chances of having a cardiac event and stent-related blood clots among patients with acute coronary syndromes.
The approval was based on results from the Phase 3 TRITON-TIMI 38 clinical trial, which compared Effient with Plavix® (clopidogrel bisulfate) in reducing cardiovascular events in 13,608 acute coronary patients managed with PCI. The study showed that Effient taken with aspirin had a 19% relative risk reduction of the combined endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke versus Plavix taken with aspirin. In addition, fewer stent-related clots were seen in patients treated with Effient compared with Plavix—a relative risk reduction of approximately 50%.
The risk of noncoronary artery bypass graft-related bleeding, which included life-threatening and fatal bleeding, was significantly higher with Effient (2.2%) compared with Plavix (1.7%). When compared with the overall treatment population, the risk of major bleeding was highest among those patients treated with Effient who were either age 75 or older, had a body weight less than 132 pounds, or had a prior history of transient ischemic attack/stroke.
Source.“Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient™.” (2009, July 10). Retrieved September 2, 2009, from http://www.medicalnewstoday.com/articles/157168.php.